Details for New Drug Application (NDA): 204809
✉ Email this page to a colleague
The generic ingredient in TADALAFIL is tadalafil. There are twenty-five drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
Pharmacology for NDA: 204809
Mechanism of Action | Phosphodiesterase 5 Inhibitors |
Medical Subject Heading (MeSH) Categories for 204809
Suppliers and Packaging for NDA: 204809
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TADALAFIL | tadalafil | TABLET;ORAL | 204809 | ANDA | Alembic Pharmaceuticals Limited | 46708-177 | 46708-177-15 | 30 TABLET, COATED in 1 CARTON (46708-177-15) |
TADALAFIL | tadalafil | TABLET;ORAL | 204809 | ANDA | Alembic Pharmaceuticals Limited | 46708-177 | 46708-177-31 | 30 TABLET, COATED in 1 BOTTLE (46708-177-31) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2.5MG | ||||
Approval Date: | Mar 26, 2019 | TE: | AB1 | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
Approval Date: | Mar 26, 2019 | TE: | AB1 | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
Approval Date: | Mar 26, 2019 | TE: | AB1 | RLD: | No |
Complete Access Available with Subscription